|
Ris-Rez Clinical Trials
3 actively recruiting trials across 3 locations
No change since September 2026
Pipeline
Phase 1: 1Phase 3: 1Phase 1/2: 1
Top Sponsors
- GlaxoSmithKline3
Indications
- Cancer3
- Neoplasms, Lung1
- Neoplasms1
- Sarcoma1
- Lung Cancer1
Los Angeles, California1 trial
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
GSK Investigational Site
Phase 3
Stanford, California1 trial
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)
GSK Investigational Site
Phase 1
West Valley City, Utah1 trial
A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)
GSK Investigational Site
Phase 1/2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.